Prof. Adnan Tufail
Prof. Tufail’s professional life has been devoted to the treatment of blinding disorders of the retina. His research has led to a better understanding of the causes and treatments of the most common of these disorders – age-related macular degeneration and diabetic retinopathy. Surgically he specialises in cataract surgery in patients with retinal disorders. He is the clinical and research lead at Moorfields Eye Hospital in London for age-related macular degeneration (AMD).
Since 2003, Prof. Tufail has been a Consultant Ophthalmologist at Moorfields Eye Hospital NHS Foundation Trust and was awarded the title of Professor at The Institute of Ophthalmology, UCL (University College London) in recognition of his contribution to eye research.
He was the lead clinician scientist for clinical trials to treat choroidal neovascularisation, including the seminal ABC Trial that focused on examining bevacizumab for neovascular AMD and the REPAIR trial for myopia related neovascularisation. Both studies had a profound effect on eyecare in the UK and internationally. His current research interests are wide ranging from disease mechanisms and treatment discovery e.g. dry age-related macular degeneration, currently an untreatable condition, to using artificial intelligence systems to improve patient access to retinal care and creating safe data sharing so that physicians can pool their patient experience to improve eye care in the NHS. He is also Deputy Lead of the large 16 million euro multicentre European study of dry age-related macular degeneration MACUSTAR.